DE60144164D1 - Transgenes Tiermodel für neurodegenerative Krankheiten - Google Patents

Transgenes Tiermodel für neurodegenerative Krankheiten

Info

Publication number
DE60144164D1
DE60144164D1 DE60144164T DE60144164T DE60144164D1 DE 60144164 D1 DE60144164 D1 DE 60144164D1 DE 60144164 T DE60144164 T DE 60144164T DE 60144164 T DE60144164 T DE 60144164T DE 60144164 D1 DE60144164 D1 DE 60144164D1
Authority
DE
Germany
Prior art keywords
transgenic animal
animal model
neurodegenerative diseases
well
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60144164T
Other languages
German (de)
English (en)
Inventor
George-Hyslop Peter H St
Paul E Fraser
David Westaway
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
Original Assignee
University of Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto filed Critical University of Toronto
Application granted granted Critical
Publication of DE60144164D1 publication Critical patent/DE60144164D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Animal Husbandry (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Eye Examination Apparatus (AREA)
DE60144164T 2000-06-20 2001-06-19 Transgenes Tiermodel für neurodegenerative Krankheiten Expired - Lifetime DE60144164D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21253400P 2000-06-20 2000-06-20

Publications (1)

Publication Number Publication Date
DE60144164D1 true DE60144164D1 (de) 2011-04-14

Family

ID=22791418

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60144164T Expired - Lifetime DE60144164D1 (de) 2000-06-20 2001-06-19 Transgenes Tiermodel für neurodegenerative Krankheiten
DE60118913T Expired - Lifetime DE60118913T2 (de) 2000-06-20 2001-06-19 Transgenes tiermodell für neurodegenerative erkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60118913T Expired - Lifetime DE60118913T2 (de) 2000-06-20 2001-06-19 Transgenes tiermodell für neurodegenerative erkrankungen

Country Status (13)

Country Link
EP (3) EP2263453B1 (enExample)
JP (3) JP4938956B2 (enExample)
AT (2) ATE499832T1 (enExample)
AU (1) AU2001270377A1 (enExample)
CA (1) CA2407847C (enExample)
CY (1) CY1105122T1 (enExample)
DE (2) DE60144164D1 (enExample)
DK (1) DK1292187T3 (enExample)
ES (1) ES2262662T3 (enExample)
MX (1) MXPA02011516A (enExample)
PT (1) PT1292187E (enExample)
SI (1) SI1292187T1 (enExample)
WO (1) WO2001097607A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100994748B1 (ko) 2002-04-19 2010-11-17 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물
US7544855B2 (en) * 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
JP4590638B2 (ja) * 2006-03-20 2010-12-01 国立大学法人鳥取大学 家族性筋萎縮性側索硬化症（ｆａｌｓ）発症するトランスジェニックマウス
CL2007002908A1 (es) 2007-10-09 2008-05-30 Univ Concepcion Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg
ES2445446T3 (es) * 2007-11-01 2014-03-03 F. Hoffmann-La Roche Ag Animales no humanos cuatro veces transgénicos
WO2010054324A2 (en) * 2008-11-10 2010-05-14 The Regents Of The University Of Colorado, A Body Corporate Methods for treating clinical conditions associated with lipoprotein lipase activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
WO1995020666A2 (en) * 1994-01-27 1995-08-03 Regents Of The University Of Minnesota Transgenic non-human mammals with progressive neurologic disease
CA2221986A1 (en) * 1995-06-07 1996-12-19 Athena Neurosciences, Inc. Method for identifying alzheimer's disease therapeutics using transgenic animal models
US5894078A (en) 1996-02-26 1999-04-13 Advanced Bioconcept, Inc. Transgenic mouse expressing C-100 app
WO1999009150A1 (en) * 1996-08-15 1999-02-25 Bayer Corporation Method of introducing modifications into a gene
US5898094A (en) * 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

Also Published As

Publication number Publication date
JP2011172600A (ja) 2011-09-08
JP4938956B2 (ja) 2012-05-23
EP1728423A3 (en) 2007-02-28
DE60118913T2 (de) 2007-01-25
EP2263453A1 (en) 2010-12-22
AU2001270377A1 (en) 2002-01-02
EP1728423B1 (en) 2011-03-02
EP1292187A2 (en) 2003-03-19
ATE499832T1 (de) 2011-03-15
CA2407847C (en) 2013-08-27
JP2009178162A (ja) 2009-08-13
MXPA02011516A (es) 2005-07-01
EP2263453B1 (en) 2018-06-13
ES2262662T3 (es) 2006-12-01
EP1728423A2 (en) 2006-12-06
DE60118913D1 (de) 2006-05-24
WO2001097607A3 (en) 2002-12-12
DK1292187T3 (da) 2006-08-21
PT1292187E (pt) 2006-07-31
ATE323408T1 (de) 2006-05-15
JP2003535605A (ja) 2003-12-02
WO2001097607A2 (en) 2001-12-27
SI1292187T1 (sl) 2006-10-31
CA2407847A1 (en) 2001-12-27
JP5070236B2 (ja) 2012-11-07
EP1292187B1 (en) 2006-04-19
CY1105122T1 (el) 2010-03-03

Similar Documents

Publication Publication Date Title
MX9708270A (es) Secuencias geneticas y proteinas relacionadas con la enfermedad de alzheimer, y uso de las mismas.
EP1319408A4 (en) MEDICINAL PRODUCTS FOR HEART FAILURE
DK0845939T3 (da) Lysosomale proteiner produceret i mælk fra ikke-humane transgene dyr
ATE343792T1 (de) Diagnostika und therapeutika für maculare degeneration
PL362437A1 (en) Diagnostics and therapeutics for glaucoma
ATE541923T1 (de) Transgener c. elegans als modellorganismus für untersuchungen zur alzheimer'schen krankheit
AU6264996A (en) Method for identifying alzheimer's disease therapeutics usin g transgenic animal models
ATE499832T1 (de) Transgenes tiermodel für neurodegenerative krankheiten
WO2003026395A3 (en) Mo54 gene disruptions, compositions and methods related thereto
CY1110788T1 (el) Διαγονιδιακα ζωα τα οποια παρουσιαζουν σημαντικες διαταραχες σχετικες με την νοσο alzheimer
SE0400707D0 (sv) Transgenic animal model
ATE473009T1 (de) Hemmung der neurodegeneration
ATE332078T1 (de) Tiermodel für neurodegenerative erkrankungen
DE60004961D1 (de) Analytisches Verfahren zur Beurteilung von nicht-humanen Tiermodellen für neurofibrilläre Degenerationserkrankungen
WO2002101232A3 (en) Bace interacting proteins
WO2002003788A3 (en) Transgenic mice containing targeted phosphatase gene disruptions
EP1391506A4 (en) ANIMAL WITH GENE HYPOEXPRESSION
BR0107845A (pt) Diagnóstico do risco de uma pessoa desenvolver alcoolismo
WO2003002714A3 (en) Protein tyrosine phosphatase 2 gene disruptions, compositions and methods related thereto
WO2002079420A3 (en) Adam-like protease disruptions, compositions and methods related thereto
WO2004062627A3 (en) In vivo screening models for treatment of alzheimer's disease and other neurodegenerative disorders
ATE428932T1 (de) Diagnostische verwendung von scn2b für alzheimer erkrankung
WO2002045497A3 (en) Transgenic mice containing dusp8 phosphatase gene disruptions
WO2002045493A3 (en) Transgenic mice containing phosphatase target gene disruptions
WO2002003790A3 (en) Transgenic mice containing targeted kinase gene disruptions